GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Bio-heart Biological Technology Co Ltd (HKSE:02185) » Definitions » Intrinsic Value: Projected FCF

Shanghai Bio-heart Biological Technology Co (HKSE:02185) Intrinsic Value: Projected FCF : HK$0.00 (As of Dec. 11, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Shanghai Bio-heart Biological Technology Co Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-12-11), Shanghai Bio-heart Biological Technology Co's Intrinsic Value: Projected FCF is HK$0.00. The stock price of Shanghai Bio-heart Biological Technology Co is HK$1.67. Therefore, Shanghai Bio-heart Biological Technology Co's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Shanghai Bio-heart Biological Technology Co's Intrinsic Value: Projected FCF or its related term are showing as below:

HKSE:02185's Price-to-Projected-FCF is not ranked *
in the Biotechnology industry.
Industry Median: 2.395
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Shanghai Bio-heart Biological Technology Co Intrinsic Value: Projected FCF Historical Data

The historical data trend for Shanghai Bio-heart Biological Technology Co's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Bio-heart Biological Technology Co Intrinsic Value: Projected FCF Chart

Shanghai Bio-heart Biological Technology Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Intrinsic Value: Projected FCF
- - - - -

Shanghai Bio-heart Biological Technology Co Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Shanghai Bio-heart Biological Technology Co's Intrinsic Value: Projected FCF

For the Biotechnology subindustry, Shanghai Bio-heart Biological Technology Co's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Bio-heart Biological Technology Co's Price-to-Projected-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shanghai Bio-heart Biological Technology Co's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Shanghai Bio-heart Biological Technology Co's Price-to-Projected-FCF falls into.



Shanghai Bio-heart Biological Technology Co Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)



Shanghai Bio-heart Biological Technology Co  (HKSE:02185) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Shanghai Bio-heart Biological Technology Co's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=1.67/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shanghai Bio-heart Biological Technology Co Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Shanghai Bio-heart Biological Technology Co's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Bio-heart Biological Technology Co Business Description

Traded in Other Exchanges
N/A
Address
No.590 Ruiqing Road, Room 302, 3rd Floor, Building 4 & Building 6, East Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, CHN
Shanghai Bio-heart Biological Technology Co Ltd is engaged in the research and development of bioresorbable scaffold (BRS) products and the renal denervation (RDN) system. The company is a interventional cardiovascular device company in China, and locate in Shanghai Zhangjiang Hi-Tech Park Medical Device Industrial Park. Focused on two therapies, bioresorbable scaffolds (BRS) and renal denervation (RDN), addressing the unmet medical needs of Chinese patients for the treatment of coronary and peripheral artery diseases and uncontrolled hypertension.
Executives
Wang Nengguang 2201 Interest of corporation controlled by you
Magic Grace Limited 2101 Beneficial owner
Loft Success Investments Limited 2201 Interest of corporation controlled by you
Lc Healthcare Fund Ii, L.p. 2201 Interest of corporation controlled by you
Lc Healthcare Fund Ii Gp Limited 2201 Interest of corporation controlled by you
Lc Fund Gp Limited 2201 Interest of corporation controlled by you
Great Unity Fund I, L.p. 2201 Interest of corporation controlled by you
Chen Hao 2201 Interest of corporation controlled by you
Proud Solar Limited 2201 Interest of corporation controlled by you
Right Lane Limited 2201 Interest of corporation controlled by you
Sk China Company Limited 2201 Interest of corporation controlled by you
Union Season Holdings Limited 2201 Interest of corporation controlled by you
Zhu Linan 2201 Interest of corporation controlled by you
Lian Xiang Kong Gu Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you
Bei Jing Jun Qi Jia Rui Qi Ye Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you

Shanghai Bio-heart Biological Technology Co Headlines

No Headlines